Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 26 2024
0mins
Should l Buy ?
Source: PRnewswire
Approval of Kinpeygo: The European Commission has granted full marketing authorization for Kinpeygo, the first fully approved medication for primary immunoglobulin A nephropathy (IgAN), expanding its use to a broader patient population based on new clinical trial data.
Financial Impact and Exclusivity: This approval triggers a €10 million milestone payment to Calliditas and confirms Kinpeygo's status as an orphan drug with 10-year market exclusivity in the EU, Iceland, Norway, and Liechtenstein.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
